about
Sunitinib: the antiangiogenic effects and beyondThe emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognitionTargeting prohibitins induces apoptosis in acute myeloid leukemia cells.NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia.The expression profile and prognostic value of APE/Ref-1 and NPM1 in high-grade serous ovarian adenocarcinoma.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.What are the latest advancements in acute myeloid leukemia therapy?Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Order Matters: The Order of Somatic Mutations Influences Cancer Evolution.A framework for understanding and targeting residual disease in oncogene-driven solid cancers.Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation.GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid LeukemiaFMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.ZGDHu-1 for cancer therapy.MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia.
P2860
Q28066499-7F5B3F5E-9438-4DC0-9CCA-30B616CB6D12Q30252512-234AD98D-1A4D-4907-A8C5-9C8649607348Q33732661-C50382EF-7FB7-47EE-8B38-1465CD3EF94DQ33761979-7694DA19-F215-4624-8281-B61FB607EB2AQ37662175-04FF4C93-A00F-48D8-A9C6-D0174108D285Q37729001-DA7468C0-6796-4E84-8DE3-466BAFEE0D59Q38647236-8C4F2A59-7FE9-4DB4-8636-F3294C96D877Q38672646-FE9989BB-B4D5-4F0C-8175-D9E9FA25B123Q38749830-21B00E11-905B-49DD-9AB0-C919FE4650C3Q38913785-173870D2-703D-49B9-99B7-A3352941AC9CQ39092636-E8364EE8-B138-4A92-9073-DCD8AC5E0CC7Q41908997-164E7D18-96B1-4C32-842D-26F43A986270Q41999207-A04147B5-6340-429A-A2E9-804E69E0F47EQ42353379-53C0340F-02FC-478E-897E-255D42937EF5Q42694670-48B449B1-64CE-46A5-B3FF-CE85F4211AAEQ49181559-43BCCDD9-1798-4723-A527-6033FD5C9A86Q49436424-8235DEDA-EDF0-4B1A-9282-BE9278BBABBAQ50066248-4EEF3459-BB44-43D8-AB95-DDFB0313D9E4
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Molecular therapy for acute myeloid leukaemia.
@ast
Molecular therapy for acute myeloid leukaemia.
@en
type
label
Molecular therapy for acute myeloid leukaemia.
@ast
Molecular therapy for acute myeloid leukaemia.
@en
prefLabel
Molecular therapy for acute myeloid leukaemia.
@ast
Molecular therapy for acute myeloid leukaemia.
@en
P2860
P1476
Molecular therapy for acute myeloid leukaemia.
@en
P2093
Catherine C Coombs
Ross L Levine
P2860
P2888
P304
P356
10.1038/NRCLINONC.2015.210
P407
P577
2015-12-01T00:00:00Z
P6179
1032618006